Intended for healthcare professionals

Feature Investigation

Rivaroxaban: can we trust the evidence?

BMJ 2016; 352 doi: (Published 03 February 2016) Cite this as: BMJ 2016;352:i575

Re: Rivaroxaban: can we trust the evidence?

Previous articles by des spence and a rapid response last week re the real risks of af make this article even more scaring. We like most GP routinely review our pts with af and advice nearly all of them to be anti coagulated. Anecdotal evidence with all the bias this bring in Hints that just in our practice unexplained significant drops in haemaglobin without overt acute bleeds are not rare in those on Noacs and this product is the CCG favourite due to its cost. Indeed were all those in our CCG put on a noac the savings using this product are I understand about £300,000 compared to other Noacs. As the CCG has no spare money we really need a true comparison between products and also need for treatment vs risks especially in those with chads score of only 1 -over a lifetime of treatment . I remain a firm believer in preventing strokes but ultimately it is patient choice.

Competing interests: No competing interests

05 February 2016
Nicholas Sharvill
Balmoral deal